PSE
4.11.2016 17:05:12 CET | Business Wire | Press release
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced the winners of the prestigious PSE Model-Based Innovation (MBI) Prize for 2016.
PSE, providers of the world-leading gPROMS® process modelling platform, awards an annual €3000 winner’s prize and two runners-up prizes of €1000 each for the most innovative use of advanced process modelling techniques in support of published research. The prizes will be awarded at a reception on Wednesday 16 November at the AIChE Annual Meeting in San Francisco.
The winners of the main prize are Jose Romagnoli, Navid Ghadipasha and Aryan Geraili of Louisiana State University, Carlos Castor Jr and Wayne Reed of Tulane University, and Michael Drenski of Advanced Polymer Monitoring Technologies, Inc., for their paper Combining On-Line Characterization Tools with Modern Software Environments for Optimal Operation of Polymerization Processes, published in Processes 2016.
The judges summarised the research presented in the paper as “an excellent piece of work demonstrating an integrated framework for the dynamic modelling, simulation, estimation, optimisation and feedback control of a polymerisation process”.
Runners up were Ioscani Jimenez del Val of University College Dublin, Yuzhou Fan of Technical University of Denmark and Dietmar Weilguny of Symphogen A/S, Denmark, for their paper Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework , and Yanan Cao and Christopher Swartz of McMaster University and Jesus Flores-Cerrillo and Jingran Ma of Praxair Inc. for their paper Dynamic Modeling and Collocation-Based Model Reduction of Cryogenic Air Separation Units . Full details can be found on the PSE website .
The prize is judged by team of leading academics in the field of process systems engineering, Prof. Stratos Pistikopoulos (chair) of Texas A&M Energy Institute, Associate Prof. Michael Georgiadis of the Aristotle University of Thessaloniki, Greece and Prof. Eva Sorensen of University College London.
gPROMS is widely used throughout the chemicals, energy, petrochemical, food and pharmaceuticals sectors, including in some 200 academic organisations. Mark Matzopoulos, deputy MD, says “PSE works closely with academic communities around the world to foster innovation, through our academic programme, the MBI Prize, our Partnerships for Advanced Process Modelling and the PSE Academic Teaching Highway (PATH). We congratulate our winners on the quality of their work.”
View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005758/en/
Contact:
Process Systems Enterprise
Contact:
Kate Burness
+44-20-8563-0888
k.burness@psenterprise.com
Editors:
www.psenterprise.com/news/pr161102
Link:
Social Media:
https://www.facebook.com//Process-Systems-Enterprise-Limited-PSE-194030330653358/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom